We’ve all been told this vitamin is good for us…‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎



<[link removed]>

September 02


 



The Vitamin 8 in 10 Americans Take—But Shouldn’t

Find Out More →
<[link removed]>

 






We’ve all been told this vitamin is good for us…

But shocking new Harvard research shows it may actually fuel deadly crystal
buildup in your arteries leading to heart failure.

And here’s the kicker:
It’s in the top 5 supplements sold in the U.S. right now.

<[link removed]>
So there’s a good chance you’ve got it sitting in your cabinet.

Before you take another dose, please check this out:



See why Amazon, Costco and other retailers are silently discontinuing this
vitamin
<[link removed]>


If you'd rather not receive these emails, you can unsubscribe here
<[link removed]>
.
 








CONNOR'S HEALTH NOTES

Calcium in an Artery Is a Marker Before It Is a Cause

Connor Hill · InsightfulWord · September 2, 2026

Nothing here is a reason to start or stop any supplement or prescribed
medication. That decision belongs with the clinician who knows the case. What
follows is about how arterial calcium is measured and what the number means,
which is a separate question and a well-documented one.

Calcification in a coronary artery is one of the most studied findings in
cardiovascular medicine, and its interpretation contains a genuine paradox that
is worth understanding before any claim about it can be assessed.

The paradox is this. The presence of calcium indicates that atherosclerosis is
present, and more of it indicates more disease and higher risk. But
calcification is also the process by which an unstable plaque becomes a stable
one, and a treatment known to reduce heart attacks measurably increases the
calcium score.

Both of those statements are supported. They are not in conflict once the
measurement is understood, because the score that is used to summarize calcium
is constructed in a way that weights the density of the deposit, and density is
precisely what increases when a plaque stabilizes.

That construction was reasonable when it was devised in 1990 and remains
clinically useful, but it means a rising score has two entirely different
possible interpretations, and distinguishing them requires knowing what else
changed.

The broader point extends past cardiology. A biological finding that appears
where disease is present is not automatically the mechanism of the disease, and
it may be the body's response to it. Scar tissue appears where injury occurred.
Fever appears with infection. Neither is the pathology.

Confusing the marker with the cause supports a familiar and rhetorically
powerful move: identify something present in diseased tissue, identify a
dietary source of it, and conclude that consuming the source produced the
disease. The chain has a missing link at every joint.

What follows is how the score is computed, why density cuts both ways, what
the score predicts and what it does not, the comparison that breaks under
treatment, and when the scan actually changes a decision.

How the Score Is Actually Computed

The standard summary is the Agatston score, and its arithmetic explains most
of the interpretive difficulty.

A computed tomography scan of the heart is acquired without contrast. Within
each image slice, regions of calcification are identified as areas exceeding a
fixed radiodensity threshold, measured in Hounsfield units — the scale on which
water is zero and dense bone is well above a thousand.

Each identified area is then multiplied by a weighting factor determined by
the maximum density within it. The factor increases in steps as the peak
density rises. The weighted areas are summed across all slices and all coronary
vessels, producing a single number.

The consequence of that design is that a large area of low-density
calcification and a small area of very dense calcification can produce similar
scores, and that increasing the density of an existing deposit raises the score
without any new territory being involved.

The categories in common use are conventional rather than biological: zero,
one to ninety-nine, one hundred to three hundred and ninety-nine, and four
hundred or above, with the boundaries chosen for practical stratification.

Alternative measures exist and are computed from the same scan. Calcium volume
ignores density entirely. Calcium mass approximates the actual quantity of
mineral. Density can be reported separately as a mean. Each answers a different
question, and the fact that three summaries can be derived from one scan is
itself an indication that no single one captures everything.


Why Density Cuts Both Ways

The behavior of the score under treatment is where the interpretive problem
becomes concrete and clinically consequential.


🩹 Health Stat of the Day

Zero

The coronary artery calcium score most strongly associated with low near-term
cardiovascular event rates in asymptomatic adults, and the reason the scan is
used mainly to reclassify people whose risk estimate sits near a treatment
threshold. The score weights each calcified area by its peak density, which is
why lipid-lowering treatment — which stabilizes plaque and increases its
density — can raise the score while reducing events. Source: American College
of Cardiology, the Agatston score in statin users.


Support or oppose: should a calcium score be reported alongside plaque volume
and density rather than as a single number?

Supporters argue that the composite score confounds extent with stability,
that both components are already computed from the same scan, and that a
clinician reading three numbers is better informed than one reading a total
that can rise for opposite reasons. Opponents answer that the single score is
what decades of outcome data are calibrated against, that adding components
invites inconsistent interpretation without new outcome evidence to anchor
them, and that a familiar imperfect measure beats an unvalidated better one.
Which is better?Hit reply — one line is enough.

Lipid-lowering therapy reduces cardiovascular events. That is established
across a very large randomized evidence base and is not in dispute.

The same therapy is associated with an increase in measured coronary calcium.
Plaques treated this way tend to develop denser, more consolidated
calcification, and the density weighting in the score converts that
stabilization into a higher number.

So a patient on treatment can return a rising score while their actual risk
has fallen. The score went up because the plaque became the kind of plaque that
is less likely to rupture.

This has a direct consequence for research. A population of people with high
scores contains both those with extensive unstable disease and those with
stabilized, densely calcified disease at considerably lower risk. Mixing them
weakens the observed association between score and events, which is why the
score performs differently in treated and untreated populations.

The general lesson is that a measurement designed as a marker of disease
burden can be moved by a process that reduces harm, and that when this happens
the direction of the number stops being interpretable on its own.


What the Score Predicts and What It Does Not

The evidence on prediction is extensive, and the boundaries of the claim are
as important as the claim.


Context — the symptoms that are not a screening question

Chest pain or pressure, pain radiating to the arm, jaw or back, breathlessness
that is new or worse on exertion, fainting, or a sudden inability to do
something that was manageable last week — these are not questions about a
screening scan or a supplement. They call for medical attention, and in the
case of chest pain with sweating, nausea or breathlessness, for emergency
services rather than an appointment. Everything below concerns risk estimation
in people who currently have no symptoms.

The score adds predictive information beyond conventional risk factors in
asymptomatic adults. That has been shown in large prospective cohorts followed
for many years, and it is the basis for the scan's place in prevention
guidelines.

Its strongest use is at the low end. A score of zero in an asymptomatic person
is associated with a low rate of events over the following several years, and
it is that finding, more than any high-score finding, that changes management —
by supporting a decision not to begin treatment in someone whose calculated
risk was borderline.

What the score does not do is diagnose. It does not identify blockages, does
not measure how much a vessel is narrowed, and does not assess whether blood
flow is limited. Those require different tests entirely.

It also does not detect the disease that has not calcified yet. Non-calcified
plaque exists, is not visible on this scan, and matters — which is why a zero
score in a person with symptoms is not reassuring in the way a zero score in an
asymptomatic person is.

And it is a risk estimate for a population, not a prediction for an
individual. A low-risk group still contains people who have events; the score
changes the probability, not the outcome.


The Comparison That Breaks Under Treatment

The reason all of this bears on claims about supplements is that the same
structural problem defeats most observational studies in this area.

A study comparing people who take something to people who do not is comparing
groups that differ in far more than the thing. People take supplements for
reasons — a doctor suggested it, a test came back low, a diagnosis was made, a
family history exists. Those reasons are also risk factors.

The technical name is confounding by indication, and it produces effects in
either direction depending on why people take the substance. Where it is taken
by people already unwell, it looks harmful. Where it is taken by the
health-conscious, it looks protective.

Statistical adjustment helps only for factors that were measured, which is why
observational studies of the same supplement routinely disagree, and why
randomized trials in this area have so often failed to confirm the
observational finding.

The same applies to the calcium finding specifically. People with higher
measured calcium differ systematically from people with less, and any substance
more common among them will appear associated with it.

What would settle a causal claim is a randomized trial with the calcium
measurement or clinical events as a pre-specified outcome. Those exist for some
supplements and not for others, and where they exist their results are the
answer regardless of how many observational studies point elsewhere.

There is a second requirement that is easy to overlook. A trial has to be long
enough for the outcome to occur. Arterial calcification develops over decades,
and a trial running two or three years with a calcium endpoint is measuring a
change in a slow process against the precision of the scanner. Where such
trials report no difference, the finding is frequently uninformative rather
than reassuring, and the distinction belongs in any summary of them.


When the Scan Changes a Decision

The practical question for anyone encountering this test is narrow, and the
guidelines are explicit about it.

The scan is used to refine risk estimation in asymptomatic adults whose
calculated risk sits in an intermediate band — where the decision about
preventive treatment is genuinely uncertain and additional information could
move it either way.

Below that band, the estimated benefit of treatment is small enough that a
scan is unlikely to change anything. Above it, treatment is indicated on the
calculated risk alone and a scan adds cost without altering the decision.

For someone already on preventive treatment, a repeat scan is generally not
informative for the reason described above: the score can rise while the
treatment is working, and no threshold exists for interpreting that rise.

There are costs on the other side. The scan involves radiation, though a
modest dose by cardiac imaging standards. It produces incidental findings in
the lungs and elsewhere that generate follow-up, some of which is unnecessary.
And it can produce false reassurance in the presence of non-calcified disease.

There is also a sequencing point. The decision that the scan informs is
whether to begin preventive treatment, which means the scan belongs before that
decision rather than after it. Ordering it in someone already treated, or in
someone whose risk is high enough that treatment is indicated regardless,
produces a number that cannot change the plan.

The composite point is that arterial calcium is a well-measured marker whose
summary score can move for opposite reasons, that its most valuable result is a
zero in an asymptomatic person near a decision threshold, and that a finding of
calcium in an artery is a description of what is there rather than an account
of how it arrived.


The bill, not the debate

A coronary calcium score weights each deposit by its density, which is why
treatment that stabilizes plaque and reduces heart attacks can raise the score.
Calcification marks disease and is also part of the repair. When a substance is
named as the cause of arterial calcium, is a randomized trial cited, or a
comparison between people who differ in many other ways?Connor Hill reads every
reply.


Sources checked: American College of Cardiology — the Agatston coronary artery
calcium score in statin users
<[link removed]>
·Journal of the American College of Cardiology — coronary calcium score and
cardiovascular risk <[link removed]> ·
JACC Cardiovascular Imaging — evolving role of calcium density in coronary
artery calcium scoring <[link removed]> ·
Multi-Ethnic Study of Atherosclerosis — study design and cardiovascular outcomes
<[link removed]> · National Heart, Lung, and Blood Institute —
coronary heart disease and risk assessment
<[link removed]> · U.S. Preventive
Services Task Force — statin use for primary prevention of cardiovascular
disease
<[link removed]>


Connor Hill · InsightfulWord





You’re receiving this email from Insightful Word (IW), a brand of TerraTrance
Technologies, LLC.

Our mailing address: 200 Broadway Blvd NEAlbuquerque, NM 87102



Have a question or need assistance? Reply directly to this email or contact us
[email protected] <mailto:[email protected]>



The content of this email may not be copied, reproduced, forwarded, shared, or
distributed without the prior written consent of TerraTrance Technologies, LLC.

Privacy Policy <[link removed]>
Terms & Conditions <[link removed]>
Unsubscribe
<[link removed]>



© 2026 Insightful Word (IW). All Rights Reserved.